cox 189 has been researched along with Acute Liver Injury, Drug-Induced in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 12 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kaniwa, N; Saito, Y | 1 |
| Bell, CJ; Eckstein, RP; Fok, KC; Jones, BE; Read, RB | 1 |
| Aklillu, E; Makonnen, E; Petros, Z | 1 |
| Besz, D; Brune, K; Cheremina, O; Hinz, B; Renner, B; Zolk, O | 1 |
| Fontana, RJ; Tujios, S | 1 |
| Ghiculescu, RA; Lampe, G; Macdonald, GA; Pillans, PI; Wilson, R; Wong, R | 1 |
| Chitturi, S; Farrell, GC | 1 |
| Hawkins, MT; Lewis, JH | 1 |
| Brune, K | 1 |
| Fleischmann, R; Notter, M; Patel, NP; Reginster, JY; Sallstig, P; Tannenbaum, H | 1 |
4 review(s) available for cox 189 and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury.
Topics: Alleles; Allopurinol; Amoxicillin-Potassium Clavulanate Combination; Azetidines; Benzylamines; Carbamazepine; Chemical and Drug Induced Liver Injury; Diclofenac; Dideoxynucleosides; Drug Hypersensitivity; Floxacillin; Genetic Markers; HLA Antigens; HLA-A Antigens; HLA-B Antigens; HLA-DQ alpha-Chains; Humans; Lapatinib; Pharmacogenetics; Quinazolines; Skin; Stevens-Johnson Syndrome; Ticlopidine | 2013 |
Mechanisms of drug-induced liver injury: from bedside to bench.
Topics: Acetaminophen; Animals; Azetidines; Benzylamines; Chemical and Drug Induced Liver Injury; Diclofenac; Floxacillin; Humans; Inactivation, Metabolic; Mice; Mitochondria, Liver; Models, Animal | 2011 |
Latest advances in predicting DILI in human subjects: focus on biomarkers.
Topics: Antitubercular Agents; Apolipoproteins E; Arylamine N-Acetyltransferase; Azetidines; Benzylamines; Biomarkers; Chemical and Drug Induced Liver Injury; Diclofenac; Floxacillin; HLA-B Antigens; Humans; Liver; Metabolomics; Pharmacogenetics; Polymorphism, Genetic; Proteomics; Risk Factors | 2012 |
1 trial(s) available for cox 189 and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.
Topics: Aged; Arthralgia; Canada; Cardiovascular Diseases; Celecoxib; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Europe; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Osteoarthritis; Pain Measurement; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome; United States | 2008 |
10 other study(ies) available for cox 189 and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Lumiracoxib-induced cholestatic liver injury.
Topics: Aged, 80 and over; Chemical and Drug Induced Liver Injury; Cholestasis; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Humans | 2013 |
Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation.
Topics: Amoxicillin-Potassium Clavulanate Combination; Cell Adhesion Molecules; Chemical and Drug Induced Liver Injury; Diclofenac; Floxacillin; Genome-Wide Association Study; Genotype; HLA-B Antigens; HLA-DQ beta-Chains; HLA-DRB1 Chains; Humans; Lapatinib; Liver; Proteins; Quinazolines | 2017 |
Lumiracoxib inhibits cyclo-oxygenase 2 completely at the 50 mg dose: is liver toxicity avoidable by adequate dosing?
Topics: Chemical and Drug Induced Liver Injury; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Humans; Monocytes | 2009 |
Severe acute liver injury associated with lumiracoxib.
Topics: Acute Disease; Autoantibodies; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2 Inhibitors; Diclofenac; Fatal Outcome; Female; Humans; Liver Transplantation; Middle Aged; Osteoarthritis | 2012 |
Lessons from Lumiracoxib: are cyclooxygenase-2 inhibitors less hepatotoxic than non-selective non-steroidal anti-inflammatory drugs?
Topics: Chemical and Drug Induced Liver Injury; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Humans | 2012 |
[Lumiracoxib taken off the market in Australia. What does that mean for our patients? (interview by Dr. Judith Neumaier)].
Topics: Australia; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Drug and Narcotic Control; Germany; Humans; Risk Factors | 2007 |